Grant: Collaborative Health Research Projects
Université de Montréal
$78,719.00
Treatment of Age Related Macular Degeneration with CD36 Receptor Modulators
FY 2016-17
Summary
Age Related Macular Degeneration (AMD) is the leading cause of blindness in Canada. Nearly 80,000 Canadians wereestimated to be affected with AMD and as our population ages this number is expected to grow at a rate of 10,000 per year.A common eye condition among people age 50 and older, AMD leads to the destruction of the macular, the part of the eye,which is made up of millions of light-sensing cells that provide sharp, detailed central vision needed for seeing objectsclearly. AMD occurs in two forms ""dry"" and ""wet"". In the former, the light-sensitive cells in the macular break down, graduallyblurring central vision in the eye. Dry AMD progresses to wet AMD, which features abnormal blood vessel growth causingswelling and damage to the macular, resulting in central vision loss. Presently, few treatments exist to slow the progressionof wet AMD and no therapy is available to treat dry AMD.The proposed project brings together experts in pharmacology, pharmacy and chemistry to tackle AMD. Our team hasidentified a scavenger receptor called CD36 as a target for AMD therapy and has synthesized molecules which modulatethis receptor. These molecules have demonstrated efficacy in cell based and animal models of AMD. The proposed researchwill further develop the molecules to understand the importance of the CD36 receptor in the various stages of AMD towardsthe development of drug candidates for treating both the dry and wet forms of AMD. In addition to exploring a novelintervention for treating the unmet medical need of AMD, our team collectively provides a unique environment for traininghigh quality personnel in the various activities of the drug discovery process from lead molecule to preclinical evaluations ofbest candidates in animal models. Graduates from this multidisciplinary program are well prepared to find employment andaddress modern challenges in academic and industrial sectors.
Program
Collaborative Health Research Projects
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
462488-2014
Name nom
Lubell, William
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2014
Award amount
78719
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
3
Nb partie
3
Application title
Treatment of Age Related Macular Degeneration with CD36 Receptor Modulators
Keyword
NSERC
Application summary
Age Related Macular Degeneration (AMD) is the leading cause of blindness in Canada. Nearly 80,000 Canadians wereestimated to be affected with AMD and as our population ages this number is expected to grow at a rate of 10,000 per year.A common eye condition among people age 50 and older, AMD leads to the destruction of the macular, the part of the eye,which is made up of millions of light-sensing cells that provide sharp, detailed central vision needed for seeing objectsclearly. AMD occurs in two forms ""dry"" and ""wet"". In the former, the light-sensitive cells in the macular break down, graduallyblurring central vision in the eye. Dry AMD progresses to wet AMD, which features abnormal blood vessel growth causingswelling and damage to the macular, resulting in central vision loss. Presently, few treatments exist to slow the progressionof wet AMD and no therapy is available to treat dry AMD.The proposed project brings together experts in pharmacology, pharmacy and chemistry to tackle AMD. Our team hasidentified a scavenger receptor called CD36 as a target for AMD therapy and has synthesized molecules which modulatethis receptor. These molecules have demonstrated efficacy in cell based and animal models of AMD. The proposed researchwill further develop the molecules to understand the importance of the CD36 receptor in the various stages of AMD towardsthe development of drug candidates for treating both the dry and wet forms of AMD. In addition to exploring a novelintervention for treating the unmet medical need of AMD, our team collectively provides a unique environment for traininghigh quality personnel in the various activities of the drug discovery process from lead molecule to preclinical evaluations ofbest candidates in animal models. Graduates from this multidisciplinary program are well prepared to find employment andaddress modern challenges in academic and industrial sectors.